TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sanofi rated AA by Scope Ratings
Paris, France - September 7, 2017 - Sanofi announced today that the European ratings agency Scope Ratings AG ("Scope") assigned the company a AA long term rating and a S-1+ short-term rating. The outlook is stable.
These ratings confirm Sanofi's high credit quality and provide investors with an increased diversity of independent opinions.
Scope is accredited and regulated by the European Securities and Markets Authority. It is the third credit rating agency to rate Sanofi, as the company is already rated AA by Standard & Poor's and A1 by Moody's. Both ratings have stable outlooks.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Media Relations Laurence Bollack Tel. : +33 (0)1 53 77 46 46 [email protected] | Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/45c5ffcc-43c1-48b7-abed-fd6c70f6f632
